Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.0025 USD
Change Today 0.00 / 0.00%
Volume 0.0
ARYX On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

aryx therapeutics inc (ARYX) Snapshot

Open
$0.0025
Previous Close
$0.0025
Day High
$0.0025
Day Low
$0.0025
52 Week High
09/16/14 - $0.02
52 Week Low
07/27/15 - $0.0018
Market Cap
83.7K
Average Volume 10 Days
11.0K
EPS TTM
$-0.58
Shares Outstanding
33.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARYX THERAPEUTICS INC (ARYX)

Related News

No related news articles were found.

aryx therapeutics inc (ARYX) Related Businessweek News

No Related Businessweek News Found

aryx therapeutics inc (ARYX) Details

ARYx Therapeutics, Inc. develops a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with commercialized drugs in the United States. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat. The company’s other clinical development products comprise ATI-7505, an oral prokinetic agent, which is in Phase IIb clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. It also focuses on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal disorders that are in discovery stage. ARYx Therapeutics, Inc. was incorporated in 1997 and is based in Fremont, California.

56 Employees
Last Reported Date: 03/30/10
Founded in 1997

aryx therapeutics inc (ARYX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARYX:US $0.00 USD 0.00

ARYX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €16.73 EUR -0.34
Ironwood Pharmaceuticals Inc $11.00 USD 0.00
Sucampo Pharmaceuticals Inc $26.88 USD +1.59
View Industry Companies
 

Industry Analysis

ARYX

Industry Average

Valuation ARYX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARYX THERAPEUTICS INC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.